Richard E. Lowenthal Sells 95,267 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal sold 95,267 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $9.12, for a total value of $868,835.04. Following the completion of the transaction, the chief executive officer now owns 1,697,447 shares of the company’s stock, valued at approximately $15,480,716.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ARS Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ SPRY opened at $9.96 on Thursday. ARS Pharmaceuticals, Inc. has a one year low of $2.55 and a one year high of $10.20. The firm has a market capitalization of $961.14 million, a PE ratio of -17.47 and a beta of 0.78. The business has a 50-day moving average price of $7.75 and a two-hundred day moving average price of $5.80.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its stake in shares of ARS Pharmaceuticals by 12.7% during the 3rd quarter. Legal & General Group Plc now owns 28,157 shares of the company’s stock worth $106,000 after purchasing an additional 3,178 shares in the last quarter. Creative Planning raised its stake in shares of ARS Pharmaceuticals by 11.7% during the 4th quarter. Creative Planning now owns 31,201 shares of the company’s stock worth $171,000 after purchasing an additional 3,270 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of ARS Pharmaceuticals by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,550 shares of the company’s stock worth $1,806,000 after purchasing an additional 5,147 shares in the last quarter. American Century Companies Inc. raised its stake in shares of ARS Pharmaceuticals by 11.1% during the 3rd quarter. American Century Companies Inc. now owns 51,521 shares of the company’s stock worth $195,000 after purchasing an additional 5,153 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock worth $31,000 after purchasing an additional 5,575 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 20th. Leerink Partnrs upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. Finally, SVB Leerink upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $6.00 to $18.00 in a research report on Tuesday, March 5th.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.